Skip to main content
HOUSE 2707118th CongressReferred to the Subcommittee on Health.

MADE in America Act

Last Action
12/17/2024

Actions

  • 2024-12-17Referred to the Subcommittee on Health.
  • 2023-04-19Referred to the House Committee on Ways and Means.
  • 2023-04-19Introduced in House
  • 2023-04-19Introduced in House

CRS Summary

As of 2023-04-19 (00)

Manufacturing API, Drugs, and Excipients in America Act or the MADE in America Act

This bill establishes a tax credit for certain manufacturers of pharmaceuticals or medical products.

Specifically, the bill establishes a tax credit for manufacturers of pharmaceuticals, active pharmaceutical ingredients, excipients (i.e., inactive ingredients), medical diagnostic devices, or personal protective equipment, if they are located in a designated distressed zone. The tax credit is equal to 25% of the manufacturer's production expenditures; the credit increases to 30% of expenditures if a substantial portion of the manufacturer's employees reside in a distressed zone.

The bill defines distressed zone as an area that has been designated as a qualified opportunity zone by the Internal Revenue Service (i.e., an economically distressed community in which certain new investments may be eligible for preferential tax treatment) and that has a poverty rate of over 30%.

Cosponsors (13)

  • Darren Soto (D-FL)
  • Carol Miller (R-WV)
  • Matt Cartwright (D-PA)
  • Richard Hudson (R-NC)
  • Gus Bilirakis (R-FL)
  • H. Griffith (R-VA)
  • Troy Balderson (R-OH)
  • Jefferson Van Drew (R-NJ)
  • Eric Crawford (R-AR)
  • Diana Harshbarger (R-TN)
  • Nicholas Langworthy (R-NY)
  • Ronny Jackson (R-TX)
  • John Rutherford (R-FL)
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.